Ni Jie, Chen Zhi, Ling Chen, Zhou Nan, Xi Yue, Wu Dan, Zhang Hejia, Liu Xiaorong
Department of Nephrology, National Center for Children's Health, Beijing Children's Hospital, Capital Medical University, Beijing, 100045, China.
Pediatr Nephrol. 2025 Jun 6. doi: 10.1007/s00467-025-06814-1.
Atypical hemolytic uremic syndrome (aHUS) is a rare disease caused by the dysregulation of the alternative pathway. The objective of this study was to evaluate the genetic background and genotype-phenotype correlations in pediatric patients with aHUS.
This retrospective study enrolled 116 pediatric patients from 2013 to 2023 in China. Here, we screened rare and common variants of atypical hemolytic uremic syndrome predisposing genes, as well as reported the clinical characteristics and extrarenal manifestations.
Genetic mutations were identified in 20% of patients. Factor H autoantibodies were detected in 53% of patients, with a homozygous CFHR1 deletion observed in 50% of them. The variant of CFHR5 p.V170M (7% vs. 0, P = 0.009, adjusted P-value = 0.036) was enriched in aHUS patients. No significant difference in the frequencies of CFH-H3 and CD46ggaac at-risk haplotypes was observed between aHUS patients and healthy controls. CFH was the most common mutation and was associated with the poorest prognosis, with a 1-year kidney survival rate of 45% after disease onset in the absence of complement blockade. Among patients with factor H autoantibodies, those with a homozygous CFHR1 deletion exhibited a significantly higher relapse rate.
Chinese children with aHUS present a low proportion of genetic mutations. Kidney outcomes significantly differ according to genetic backgrounds in the pre-complement blockade era. Homozygous CFHR1 homozygous deletion increases the risk of relapse in patients with factor H autoantibodies.
非典型溶血尿毒综合征(aHUS)是一种由替代途径失调引起的罕见疾病。本研究的目的是评估儿童aHUS患者的遗传背景及基因型-表型相关性。
本回顾性研究纳入了2013年至2023年期间中国的116例儿科患者。在此,我们筛查了非典型溶血尿毒综合征易感基因的罕见和常见变异,并报告了临床特征和肾外表现。
20%的患者检测到基因突变。53%的患者检测到H因子自身抗体,其中50%观察到CFHR1纯合缺失。CFHR5 p.V170M变异在aHUS患者中富集(7%对0,P = 0.009,校正P值 = 0.036)。在aHUS患者和健康对照之间,未观察到CFH-H3和CD46ggaac风险单倍型频率的显著差异。CFH是最常见的突变,且与最差的预后相关,在无补体阻断的情况下,发病后1年肾脏存活率为45%。在有H因子自身抗体的患者中,CFHR1纯合缺失的患者复发率显著更高。
中国儿童aHUS患者的基因突变比例较低。在补体阻断前时代,根据遗传背景,肾脏结局存在显著差异。CFHR1纯合缺失会增加有H因子自身抗体患者的复发风险。